Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple Sclerosis
|
|
- Jocelyn Glenn
- 5 years ago
- Views:
Transcription
1 Sfety of Ocrelizumb in Multiple Sclerosis: Updted Anlysis in Ptients With Relpsing nd Primry Progressive Multiple Sclerosis SL Huser, L Kppos, X Montlbn, H Koendgen, C Chognot, C Li, C Mrcillt, A Prdhn, D Wormser, JS Wolinsky Phse II (NCT676715); OPERA I (NCT ); OPERA II (NCT ); ORATORIO (NCT119457); VELOCE (NCT ); CHORDS (NCT ); CASTING (NCT286114); OBOE (NCT ) Presented t the 7th Americn Acdemy of Neurology (AAN) Annul Meeting; April 21 27, 218; Los Angeles, CA, USA Pltform presenttion number S36.1 OCR/32218/83d
2 Disclosures SL Huser serves on the bord of trustees for Neuron nd on scientific dvisory bords for Annexon, Bionure nd Symbiotix nd hs received trvel reimbursement nd writing ssistnce from F. Hoffmnn-L Roche Ltd for CD2-relted meetings nd presenttions. L Kppos s institution, the University Hospitl Bsel, hs received reserch support nd pyments tht were used exclusively for reserch support for Prof. Kppos s ctivities s principl investigtor nd member or chir of plnning nd steering committees or dvisory bords for trils sponsored by Actelion, Addex, Almirll, Byer HelthCre Phrmceuticls, CLC Behring, F. Hoffmnn-L Roche Ltd nd Genentech, Inc., GeNeuro SA, Genzyme, Merck Serono, Mitsubishi Phrm, Novrtis, Octphrm, Ono Phrmceuticl, Pfizer, Receptos, Snofi, Snther, Siemens, Tev, UCB nd XenoPort; hs received license fees for Neurosttus products; nd hs received reserch grnts from the Europen Union, Ginni Rubtto Foundtion, Novrtis Reserch Foundtion, Roche Reserch Foundtion, Swiss Multiple Sclerosis Society nd Swiss Ntionl Reserch Foundtion. H Koendgen is n employee nd shreholder of F. Hoffmnn-L Roche Ltd. C Chognot is n employee of F. Hoffmnn-L Roche Ltd. C Li is n employee of F. Hoffmnn-L Roche Ltd. C Mrcillt is n employee of F. Hoffmnn-L Roche Ltd. A Prdhn is n employee of Genentech, Inc. D Wormser is n employee nd shreholder of F. Hoffmnn-L Roche Ltd. JS Wolinsky hs served on dvisory bords nd dt monitoring or steering committees, hs held consulting greements or hs received speker honorri from AbbVie, Alkermes, Biogen, Bionest, Clene Nnomedicine, EMD Serono, F. Hoffmnn-L Roche Ltd, Forwrd Phrm, Genentech, Inc., MedDy Phrmceuticls, Novrtis, Snofi Genzyme, Tked, Tev, nd hs received roylties for monoclonl ntibodies outlicensed to Chemicon Interntionl through UTHelth. X Montlbn hs received speker honorri nd trvel expense reimbursement for prticiption in scientific meetings, been steering committee member of clinicl trils or served on dvisory bords of clinicl trils for Actelion, Almirll, Byer, Biogen, F. Hoffmnn-L Roche Ltd, Genzyme, Merck, Novrtis, Octphrm, Receptos, Snofi, Tev nd Trophos. This study ws sponsored by F. Hoffmnn-L Roche Ltd, Bsel, Switzerlnd. Writing nd editoril ssistnce for this presenttion ws provided by Articulte Science, UK, nd funded by F. Hoffmnn-L Roche Ltd, Bsel, Switzerlnd. 2
3 Proportion of ptients hving confirmed disbility progression Cumultive probbility of event (%) Adjusted ARR Totl number of new or enlrging 12 lesions per MRI scn Efficcy bckground p< OPERA OLE: ARR 1 Ptients receiving IFN β-1 44μg during the DBP Ptients switching from IFN β-1 to OCR n=829 n=827 n=713 n=765 n=623 n=72 n=594 n=665 Week 48 (DBP Yer 1) Week (DBP Yer 2) Week (Yer 3/OLE Yer 1) Week (Yer 4/OLE Yer 2) IFN β-1/ocr OCR/OCR DBP: HR=.6; p=.3.23 p< p<.1 p= OPERA OLE: CDP (24-week) 1 Strt of OLE =4.31 (1.27, 7.35); p=.5 Ptients continuing OCR 6 mg tretment p=.3 =4.85 (1.52, 8.18); p=.4 p= Immture dt =5.44 (1.97, 8.91); p=.2 =4.84 (1.16, 8.52); p=.1 =4.36 (.51, 8.22); p=.27 Bseline Time to onset of confirmed disbility progression (weeks) No. of ptients t risk IFN β-1/ocr 6 mg OCR 6 mg/ocr 6 mg p<.1 ARR, nnulized relpse rte; CDP, confirmed disbility progression; CI, confidence intervl; DBP, double-blind period; ECP, extended control period; HR, hzrd rtio; IFN, interferon; OLE, open-lbel extension; OCR, ocrelizumb; PBO, plcebo. 1. Huser SL, et l. AAN 218; Poster 366; 2. Arnold DL, et l. AAN 218; Pltform presenttion 2; 3. Wolinsky JS, et l. ECTRIMS 217; Poster OPERA OLE: New/enlrging T2 lesions 2 Ptients receiving IFN β-1 44μg during the DBP Ptients switching from IFN β-1 to OCR.761 p< p< p< n=747 n=772 n=694 n=754 n=65 n=72 n=58 n=646 n=536 n=599 Weeks 24 Weeks Weeks Yer 1 Yer 2 Weeks Yer 3 (OLE Yer 1) ORATORIO ECP: CDP (24-week) 3 PBO (N=244) OCR 6 mg (N=488) HR=.7 (95% CI.55.9); p=.5 Ptients continuing OCR 6 mg tretment Weeks Yer ~4 (OLE Yer 2) Bseline Time (weeks) No. of ptients t risk PBO OCR 6 mg
4 Bckground nd objectives In the Phse III trils, the most common dverse events (AEs) ssocited with ocrelizumb (OCR) included infusion-relted rections, nsophryngitis, upper respirtory trct infections, hedche nd urinry trct infections 1,2 Objectives: To report ongoing sfety evlutions from OCR clinicl trils nd ssocited open-lbel extension (OLE) periods up to 217 To provide n updte on the incidence rtes of mlignncies in the OCR clinicl tril progrm, in the context of dt from epidemiologicl dt sources (MS registries) nd the generl popultion (Ntionl Cncer Institute Surveillnce, Epidemiology, nd End Results dtbse) To report post-mrketing dt for ftlities nd progressive multifocl leukoencephlopthy (PML) up to Mrch 218 AEs, dverse events; MS, multiple sclerosis; OCR, ocrelizumb; OLE, open-lbel extension; PML, progressive multifocl leukoencephlopthy. 1. Huser SL, et l. N Engl J Med 217;376: ; 2. Montlbn X, et l. N Engl J Med 217;376:
5 Methods Sfety nlyses re bsed on integrted dt for ll ptients who received OCR in the following clinicl trils, s of 217 (OCR ll-exposure popultion): The Phse II nd Phse III MS clinicl trils nd ssocited OLE periods (Ph II/Ph III nd OLEs popultion) The primry nlysis ws bsed on the clinicl cut-off dtes of the individul studies VELOCE: Effect of OCR on immune responses in ptients with RMS CHORDS/CASTING: Study of OCR in ptients with RRMS with suboptiml response to disese-modifying tretment (USA/Europe) OBOE b : Mechnism of ction of OCR nd B-cell biology in ptients with RMS or PPMS AEs re reported s rtes per 1 ptient yers (PY) The number of post-mrketing ptients exposed to OCR is bsed on estimted totl number of vils sold, s well s US clims dt Phse II, Jnury 215; OPERA I, April 215; OPERA II, My 215; ORATORIO, July 215; b The clinicl cut-off dte used for OBOE ws June 217. AEs, dverse events; MS, multiple sclerosis; OCR, ocrelizumb; OLE, open-lbel extension; PPMS, primry progressive multiple sclerosis; PY, ptient yers; RMS, relpsing multiple sclerosis; RRMS, relpsing-remitting multiple sclerosis. 6
6 Tretment exposure Chrcteristic OCR ll-exposure popultion (N=3,778) Totl ptient yers 9,474 Number of doses, n (%) b,c Men (SD) number of doses Medin number of doses Totl cumultive dose, mg Men (SD) Medin Rnge Number of ptients exposed 3,778 (1) 3,271 (86.6) 2,373 (62.8) 2,78 (55.) 1,791 (47.4) 1,738 (46.) 1,542 (4.8) 1,3 (34.4) 1,121 (29.7) 1,62 (28.1) 5.7 (4.2) 4. 3,47 (2,485) 2,4 9 11,8 Dt cut-off: 217. Doses were dministered every 6 months. Includes ptients who received ny dose of OCR during the controlled tretment nd ssocited OLE periods of the Phse II nd Phse III studies, plus VELOCE, CHORDS, CASTING nd OBOE (s of 217; clinicl cut-off dte for OBOE: June 217); dt from ptients who were originlly rndomized to comprtor (IFN β-1 or plcebo) re included fter the switch to open-lbel OCR tretment; b If ptient received ny infusion in one dose, it ws counted s one dose; c More thn four doses equls more thn 2 yers exposure, nd more thn eight doses equls more thn 4 yers exposure. IFN, interferon; OCR, ocrelizumb; OLE, open-lbel extension; SD, stndrd devition. 7
7 Sfety profile observed with ocrelizumb Event OPERA (pooled) controlled tretment period ORATORIO controlled tretment period Ph II/Ph III nd OLEs popultion b OCR ll-exposure popultion c IFN β-1 rte per OCR rte per Plcebo rte per OCR rte per Sept 217 rte per Sept 217 rte per 1 PY (95% CI) d 1 PY (95% CI) d 1 PY (95% CI) d 1 PY (95% CI) d 1 PY (95% CI) d,e 1 PY (95% CI) d,e Any dverse events 296 (287 35) 29 ( ) 259 ( ) 252 (244 26) 22 ( ) 243 (24 246) Adverse events leding to study tretment discontinution 3.93 ( ) 2.35 ( ) 1.1 ( ) 1.25 ( ) 1.18 ( ) 1.9 ( ) Infections nd infesttions f,g 67.8 ( ) 84.5 ( ) 72.5 ( ) 7.8 ( ) 7.3 ( ) 73.1 ( ) Urinry trct infection Nsophryngitis Upper respirtory trct infection Bronchitis Influenz Injury, poisoning nd procedurl complictions f Infusion-relted rections Nervous system disorders h Hedche Musculoskeletl nd connective tissue disorders f Bck pin Arthrlgi Pin in extremity Generl disorders nd dministrtion site conditions f Ftigue Psychitric disorders f Depression 9.7 ( ) 8.3 ( ) 9.4 ( ) 2.2 ( ) 3.3 ( ) 17.1 ( ) 7.9 ( ) 34.8 ( ) 12.4 ( ) 25. ( ) 3.1 ( ) 3.9 (3. 5.1) 2.9 (2.1 4.) 51.3 ( ) 5.7 ( ) 14.2 ( ) 4.2 ( ) 11.6 ( ) 13. ( ) 13.3 ( ) 3.5 ( ) 3.1 ( ) 45.9 ( ) 34.9 ( ) 31.6 ( ) 9.5 ( ) 24.3 ( ) 4.1 ( ) 3.5 ( ) 3.7 ( ) 17.3 ( ) 5.4 ( ) 14.4 ( ) 4.9 ( ) 17.8 ( ) 17.7 ( ) 2.9 ( ) 2.9 ( ) 3.4 ( ) 36.3 ( ) 2.3 ( ) 22.4 ( ) 6.7 (5. 8.9) 31.7 ( ) 7.4 ( ) 4.3 (2.9 6.) 4.7 ( ) 15.6 ( ) 4.4 (3. 6.2) 11.8 ( ) 5.1 (3.6 7.) 15.1 ( ) 12.8 ( ) 5.2 ( ) 2.6 ( ) 4.6 ( ) 43.5 ( ) 31. ( ) 22.6 ( ) 6.3 ( ) 22.8 ( ) 4.8 (3.8 6.) 3. (2.2 4.) 2.4 ( ) 12.7 ( ) 1.9 ( ) 7.7 ( ) 2.4 ( ) 12.7 ( ) 1.2 (1. 1.5) 9.4 ( ) 3.1 ( ) 2.9 ( ) 31.5 ( ) 21.5 ( ) 2.6 ( ) 5.2 ( ) 19.3 ( ) 3.4 (3. 3.8) 2.8 ( ) 2.3 (2. 2.6) 1.7 ( ) 3. ( ) 7.8 ( ) 2.7 ( ) 12.8 ( ) 1.2 (1. 1.4) 9.6 (9. 1.2) 3.1 ( ) 3.1 ( ) 38.8 ( ) 28.4 ( ) 24.2 ( ) 7. ( ) 2.9 ( ) 3.7 ( ) 3. ( ) 2.7 ( ) 12.8 ( ) 3.7 ( ) 8.6 (8. 9.2) 2.8 ( ) Mlignncies i,j.14 (.2.52).28 (.8.71).27 (.3.99).93 ( ).51 (.37.68).48 (.35.64) Serious dverse events Serious infections k Number of confirmed serious OIs 6.29 ( ) 1.79 ( ) 5.39 ( ).83 ( ) 12.7 ( ) 3.2 ( ) 1.15 ( ) 2.74 ( ) 7.42 ( ) 2.1 ( ) ( ) 1.96 ( ) 1 Ftlities.14 (.2.52).7 (.38).41 (.8 1.2).25 (.7.64).18 (.11.3).17 (.1.27) Includes ptients who received plcebo or IFN β-1 during the controlled tretment period of the Phse III studies; b Includes ptients who received ny dose of OCR during the controlled tretment nd ssocited OLE periods of the Phse II nd Phse III studies; dt from ptients who were originlly rndomized to comprtor (IFN β-1 or plcebo) re included fter the switch to open-lbel OCR tretment; c Includes ptients who received ny dose of OCR during the controlled tretment nd ssocited OLE periods of the Phse II nd Phse III studies, plus VELOCE, CHORDS, CASTING nd OBOE (s of 217; clinicl cut-off dte for OBOE: June 217); d Multiple occurrences of the sme dverse event (except for mlignncies) in one ptient re counted multiple times; e Rte per 1 PY (95% CI) s of 217; f Includes events occurring in 5% of ptients; g Includes events flling into the MedDRA versions 18., 18.1, 19.1 nd 2. SOC Infections nd Infesttions; h Non-serious MS relpses re not considered s n dverse event. If n dverse event reported term ws coded to the preferred term Multiple Sclerosis Relpse, regrdless of seriousness, it ws considered s n dverse event. When the MS relpse resulted in hospitliztion for ny reson other thn the routine tretment of the relpse, or when the hospitliztion ws prolonged, the relpse ws considered s serious dverse event; i Includes non-melnom skin cncer s per MedDRA version SMQ Mlignnt Tumours; j Reported s incidence rte per 1 PY of first mlignncy; k Serious infections re defined using dverse events flling into the MedDRA SOC Infections nd Infesttions, nd using Is the event non-serious or serious? from the dverse event cse report form. CI, confidence intervl; IFN, interferon; MedDRA, Medicl Dictionry for Regultory Activities; MS, multiple sclerosis; OCR, ocrelizumb; OIs, opportunistic infections; OLE, open-lbel extension; PY, ptient yers; SMQ, stndrdized MedDRA query; SOC, system orgn clss. 9
8 Sfety profile observed with ocrelizumb Event OPERA (pooled) controlled tretment period ORATORIO controlled tretment period Ph II/Ph III nd OLEs popultion b Includes ptients who received plcebo or IFN β-1 during the controlled tretment period of the Phse III studies; b Includes ptients who received ny dose of OCR during the controlled tretment nd ssocited OLE periods of the Phse II nd Phse III studies; dt from ptients who were originlly rndomized to comprtor (IFN β-1 or plcebo) re included fter the switch to open-lbel OCR tretment; c Includes ptients who received ny dose of OCR during the controlled tretment nd ssocited OLE periods of the Phse II nd Phse III studies, plus VELOCE, CHORDS, CASTING nd OBOE (s of 217; clinicl cut-off dte for OBOE: June 217); d Multiple occurrences of the sme dverse event (except for mlignncies) in one ptient re counted multiple times; e Rte per 1 PY (95% CI) s of 217; f Includes events occurring in 5% of ptients; g Includes events flling into the MedDRA versions 18., 18.1, 19.1 nd 2. SOC Infections nd Infesttions; h Non-serious MS relpses re not considered s n dverse event. If n dverse event reported term ws coded to the preferred term Multiple Sclerosis Relpse, regrdless of seriousness, it ws considered s n dverse event. When the MS relpse resulted in hospitliztion for ny reson other thn the routine tretment of the relpse, or when the hospitliztion ws prolonged, the relpse ws considered s serious dverse event; i Includes non-melnom skin cncer s per MedDRA version SMQ Mlignnt Tumours; j Reported s incidence rte per 1 PY of first mlignncy; k Serious infections re defined using dverse events flling into the MedDRA SOC Infections nd Infesttions, nd using Is the event non-serious or serious? from the dverse event cse report form. CI, confidence intervl; IFN, interferon; MedDRA, Medicl Dictionry for Regultory Activities; MS, multiple sclerosis; OCR, ocrelizumb; OIs, opportunistic infections; OLE, open-lbel extension; PY, ptient yers; SMQ, stndrdized MedDRA query; SOC, system orgn clss. OCR ll-exposure popultion c IFN β-1 rte per OCR rte per Plcebo rte per OCR rte per Sept 217 rte per Sept 217 rte per 1 PY (95% CI) d 1 PY (95% CI) d 1 PY (95% CI) d 1 PY (95% CI) d 1 PY (95% CI) d,e 1 PY (95% CI) d,e Any dverse events 296 (287 35) 29 ( ) 259 ( ) 252 (244 26) 22 ( ) 243 (24 246) Adverse events leding to study tretment discontinution 3.93 ( ) 2.35 ( ) 1.1 ( ) 1.25 ( ) 1.18 ( ) 1.9 ( ) Infections nd infesttions f,g 67.8 ( ) 84.5 ( ) 72.5 ( ) 7.8 ( ) 7.3 ( ) 73.1 ( ) Urinry trct infection Nsophryngitis Upper respirtory trct infection Bronchitis Influenz Injury, poisoning nd procedurl complictions f Infusion-relted rections Nervous system disorders h Hedche Musculoskeletl nd connective tissue disorders f Bck pin Arthrlgi Pin in extremity Generl disorders nd dministrtion site conditions f Ftigue Psychitric disorders f Depression 9.7 ( ) 8.3 ( ) 9.4 ( ) 2.2 ( ) 3.3 ( ) 17.1 ( ) 7.9 ( ) 34.8 ( ) 12.4 ( ) 25. ( ) 3.1 ( ) 3.9 (3. 5.1) 2.9 (2.1 4.) 51.3 ( ) 5.7 ( ) 14.2 ( ) 4.2 ( ) 11.6 ( ) 13. ( ) 13.3 ( ) 3.5 ( ) 3.1 ( ) 45.9 ( ) 34.9 ( ) 31.6 ( ) 9.5 ( ) 24.3 ( ) 4.1 ( ) 3.5 ( ) 3.7 ( ) 17.3 ( ) 5.4 ( ) 14.4 ( ) 4.9 ( ) 17.8 ( ) 17.7 ( ) 2.9 ( ) 2.9 ( ) 3.4 ( ) 36.3 ( ) 2.3 ( ) 22.4 ( ) 6.7 (5. 8.9) 31.7 ( ) 7.4 ( ) 4.3 (2.9 6.) 4.7 ( ) 15.6 ( ) 4.4 (3. 6.2) 11.8 ( ) 5.1 (3.6 7.) 15.1 ( ) 12.8 ( ) 5.2 ( ) 2.6 ( ) 4.6 ( ) 43.5 ( ) 31. ( ) 22.6 ( ) 6.3 ( ) 22.8 ( ) 4.8 (3.8 6.) 3. (2.2 4.) 2.4 ( ) 12.7 ( ) 1.9 ( ) 7.7 ( ) 2.4 ( ) 12.7 ( ) 1.2 (1. 1.5) 9.4 ( ) 3.1 ( ) 2.9 ( ) 31.5 ( ) 21.5 ( ) 2.6 ( ) 5.2 ( ) 19.3 ( ) 3.4 (3. 3.8) 2.8 ( ) 2.3 (2. 2.6) 1.7 ( ) 3. ( ) 7.8 ( ) 2.7 ( ) 12.8 ( ) 1.2 (1. 1.4) 9.6 (9. 1.2) 3.1 ( ) 3.1 ( ) 38.8 ( ) 28.4 ( ) 24.2 ( ) 7. ( ) 2.9 ( ) 3.7 ( ) 3. ( ) 2.7 ( ) 12.8 ( ) 3.7 ( ) 8.6 (8. 9.2) 2.8 ( ) Mlignncies i,j.14 (.2.52).28 (.8.71).27 (.3.99).93 ( ).51 (.37.68).48 (.35.64) Serious dverse events Serious infections k Number of confirmed serious OIs 6.29 ( ) 1.79 ( ) 5.39 ( ).83 ( ) 12.7 ( ) 3.2 ( ) 1.15 ( ) 2.74 ( ) 7.42 ( ) 2.1 ( ) ( ) 1.96 ( ) 1 Ftlities.14 (.2.52).7 (.38).41 (.8 1.2).25 (.7.64).18 (.11.3).17 (.1.27) 1
9 Sfety profile observed with ocrelizumb Event OPERA (pooled) controlled tretment period ORATORIO controlled tretment period Ph II/Ph III nd OLEs popultion b Includes ptients who received plcebo or IFN β-1 during the controlled tretment period of the Phse III studies; b Includes ptients who received ny dose of OCR during the controlled tretment nd ssocited OLE periods of the Phse II nd Phse III studies; dt from ptients who were originlly rndomized to comprtor (IFN β-1 or plcebo) re included fter the switch to open-lbel OCR tretment; c Includes ptients who received ny dose of OCR during the controlled tretment nd ssocited OLE periods of the Phse II nd Phse III studies, plus VELOCE, CHORDS, CASTING nd OBOE (s of 217; clinicl cut-off dte for OBOE: June 217); d Multiple occurrences of the sme dverse event (except for mlignncies) in one ptient re counted multiple times; e Rte per 1 PY (95% CI) s of 217; f Includes events occurring in 5% of ptients; g Includes events flling into the MedDRA versions 18., 18.1, 19.1 nd 2. SOC Infections nd Infesttions; h Non-serious MS relpses re not considered s n dverse event. If n dverse event reported term ws coded to the preferred term Multiple Sclerosis Relpse, regrdless of seriousness, it ws considered s n dverse event. When the MS relpse resulted in hospitliztion for ny reson other thn the routine tretment of the relpse, or when the hospitliztion ws prolonged, the relpse ws considered s serious dverse event; i Includes non-melnom skin cncer s per MedDRA version SMQ Mlignnt Tumours; j Reported s incidence rte per 1 PY of first mlignncy; k Serious infections re defined using dverse events flling into the MedDRA SOC Infections nd Infesttions, nd using Is the event non-serious or serious? from the dverse event cse report form. CI, confidence intervl; IFN, interferon; MedDRA, Medicl Dictionry for Regultory Activities; MS, multiple sclerosis; OCR, ocrelizumb; OIs, opportunistic infections; OLE, open-lbel extension; PY, ptient yers; SMQ, stndrdized MedDRA query; SOC, system orgn clss. OCR ll-exposure popultion c IFN β-1 rte per OCR rte per Plcebo rte per OCR rte per Sept 217 rte per Sept 217 rte per 1 PY (95% CI) d 1 PY (95% CI) d 1 PY (95% CI) d 1 PY (95% CI) d 1 PY (95% CI) d,e 1 PY (95% CI) d,e Any dverse events 296 (287 35) 29 ( ) 259 ( ) 252 (244 26) 22 ( ) 243 (24 246) Adverse events leding to study tretment discontinution 3.93 ( ) 2.35 ( ) 1.1 ( ) 1.25 ( ) 1.18 ( ) 1.9 ( ) Infections nd infesttions f,g 67.8 ( ) 84.5 ( ) 72.5 ( ) 7.8 ( ) 7.3 ( ) 73.1 ( ) Urinry trct infection Nsophryngitis Upper respirtory trct infection Bronchitis Influenz Injury, poisoning nd procedurl complictions f Infusion-relted rections Nervous system disorders h Hedche Musculoskeletl nd connective tissue disorders f Bck pin Arthrlgi Pin in extremity Generl disorders nd dministrtion site conditions f Ftigue Psychitric disorders f Depression 9.7 ( ) 8.3 ( ) 9.4 ( ) 2.2 ( ) 3.3 ( ) 17.1 ( ) 7.9 ( ) 34.8 ( ) 12.4 ( ) 25. ( ) 3.1 ( ) 3.9 (3. 5.1) 2.9 (2.1 4.) 51.3 ( ) 5.7 ( ) 14.2 ( ) 4.2 ( ) 11.6 ( ) 13. ( ) 13.3 ( ) 3.5 ( ) 3.1 ( ) 45.9 ( ) 34.9 ( ) 31.6 ( ) 9.5 ( ) 24.3 ( ) 4.1 ( ) 3.5 ( ) 3.7 ( ) 17.3 ( ) 5.4 ( ) 14.4 ( ) 4.9 ( ) 17.8 ( ) 17.7 ( ) 2.9 ( ) 2.9 ( ) 3.4 ( ) 36.3 ( ) 2.3 ( ) 22.4 ( ) 6.7 (5. 8.9) 31.7 ( ) 7.4 ( ) 4.3 (2.9 6.) 4.7 ( ) 15.6 ( ) 4.4 (3. 6.2) 11.8 ( ) 5.1 (3.6 7.) 15.1 ( ) 12.8 ( ) 5.2 ( ) 2.6 ( ) 4.6 ( ) 43.5 ( ) 31. ( ) 22.6 ( ) 6.3 ( ) 22.8 ( ) 4.8 (3.8 6.) 3. (2.2 4.) 2.4 ( ) 12.7 ( ) 1.9 ( ) 7.7 ( ) 2.4 ( ) 12.7 ( ) 1.2 (1. 1.5) 9.4 ( ) 3.1 ( ) 2.9 ( ) 31.5 ( ) 21.5 ( ) 2.6 ( ) 5.2 ( ) 19.3 ( ) 3.4 (3. 3.8) 2.8 ( ) 2.3 (2. 2.6) 1.7 ( ) 3. ( ) 7.8 ( ) 2.7 ( ) 12.8 ( ) 1.2 (1. 1.4) 9.6 (9. 1.2) 3.1 ( ) 3.1 ( ) 38.8 ( ) 28.4 ( ) 24.2 ( ) 7. ( ) 2.9 ( ) 3.7 ( ) 3. ( ) 2.7 ( ) 12.8 ( ) 3.7 ( ) 8.6 (8. 9.2) 2.8 ( ) Mlignncies i,j.14 (.2.52).28 (.8.71).27 (.3.99).93 ( ).51 (.37.68).48 (.35.64) Serious dverse events Serious infections k Number of confirmed serious OIs 6.29 ( ) 1.79 ( ) 5.39 ( ).83 ( ) 12.7 ( ) 3.2 ( ) 1.15 ( ) 2.74 ( ) 7.42 ( ) 2.1 ( ) ( ) 1.96 ( ) 1 Ftlities.14 (.2.52).7 (.38).41 (.8 1.2).25 (.7.64).18 (.11.3).17 (.1.27) 11
10 Sfety profile observed with ocrelizumb Event OPERA (pooled) controlled tretment period ORATORIO controlled tretment period Ph II/Ph III nd OLEs popultion b OCR ll-exposure popultion c IFN β-1 rte per OCR rte per Plcebo rte per OCR rte per Sept 217 rte per Sept 217 rte per 1 PY (95% CI) d 1 PY (95% CI) d 1 PY (95% CI) d 1 PY (95% CI) d 1 PY (95% CI) d,e 1 PY (95% CI) d,e Any dverse events 296 (287 35) 29 ( ) 259 ( ) 252 (244 26) 22 ( ) 243 (24 246) Adverse events leding to study tretment discontinution 3.93 ( ) 2.35 ( ) 1.1 ( ) 1.25 ( ) 1.18 ( ) 1.9 ( ) Infections nd infesttions f,g 67.8 ( ) 84.5 ( ) 72.5 ( ) 7.8 ( ) 7.3 ( ) 73.1 ( ) Urinry trct infection Nsophryngitis Upper respirtory trct infection Bronchitis Influenz Injury, poisoning nd procedurl complictions f Infusion-relted rections Nervous system disorders h Hedche Musculoskeletl nd connective tissue disorders f Bck pin Arthrlgi Pin in extremity Generl disorders nd dministrtion site conditions f Ftigue Psychitric disorders f Depression 9.7 ( ) 8.3 ( ) 9.4 ( ) 2.2 ( ) 3.3 ( ) 17.1 ( ) 7.9 ( ) 34.8 ( ) 12.4 ( ) 25. ( ) 3.1 ( ) 3.9 (3. 5.1) 2.9 (2.1 4.) 51.3 ( ) 5.7 ( ) 14.2 ( ) 4.2 ( ) 11.6 ( ) 13. ( ) 13.3 ( ) 3.5 ( ) 3.1 ( ) 45.9 ( ) 34.9 ( ) 31.6 ( ) 9.5 ( ) 24.3 ( ) 4.1 ( ) 3.5 ( ) 3.7 ( ) 17.3 ( ) 5.4 ( ) 14.4 ( ) 4.9 ( ) 17.8 ( ) 17.7 ( ) 2.9 ( ) 2.9 ( ) 3.4 ( ) 36.3 ( ) 2.3 ( ) 22.4 ( ) 6.7 (5. 8.9) 31.7 ( ) 7.4 ( ) 4.3 (2.9 6.) 4.7 ( ) 15.6 ( ) 4.4 (3. 6.2) 11.8 ( ) 5.1 (3.6 7.) 15.1 ( ) 12.8 ( ) 5.2 ( ) 2.6 ( ) 4.6 ( ) 43.5 ( ) 31. ( ) 22.6 ( ) 6.3 ( ) 22.8 ( ) 4.8 (3.8 6.) 3. (2.2 4.) 2.4 ( ) 12.7 ( ) 1.9 ( ) 7.7 ( ) 2.4 ( ) 12.7 ( ) 1.2 (1. 1.5) 9.4 ( ) 3.1 ( ) 2.9 ( ) 31.5 ( ) 21.5 ( ) 2.6 ( ) 5.2 ( ) 19.3 ( ) 3.4 (3. 3.8) 2.8 ( ) 2.3 (2. 2.6) 1.7 ( ) 3. ( ) 7.8 ( ) 2.7 ( ) 12.8 ( ) 1.2 (1. 1.4) 9.6 (9. 1.2) 3.1 ( ) 3.1 ( ) 38.8 ( ) 28.4 ( ) 24.2 ( ) 7. ( ) 2.9 ( ) 3.7 ( ) 3. ( ) 2.7 ( ) 12.8 ( ) 3.7 ( ) 8.6 (8. 9.2) 2.8 ( ) Mlignncies i,j.14 (.2.52).28 (.8.71).27 (.3.99).93 ( ).51 (.37.68).48 (.35.64) Serious dverse events Serious infections k Number of confirmed serious OIs 6.29 ( ) 1.79 ( ) 5.39 ( ).83 ( ) 12.7 ( ) 3.2 ( ) 1.15 ( ) 2.74 ( ) 7.42 ( ) 2.1 ( ) ( ) 1.96 ( ) 1 Ftlities.14 (.2.52).7 (.38).41 (.8 1.2).25 (.7.64).18 (.11.3).17 (.1.27) Includes ptients who received plcebo or IFN β-1 during the controlled tretment period of the Phse III studies; b Includes ptients who received ny dose of OCR during the controlled tretment nd ssocited OLE periods of the Phse II nd Phse III studies; dt from ptients who were originlly rndomized to comprtor (IFN β-1 or plcebo) re included fter the switch to open-lbel OCR tretment; c Includes ptients who received ny dose of OCR during the controlled tretment nd ssocited OLE periods of the Phse II nd Phse III studies, plus VELOCE, CHORDS, CASTING nd OBOE (s of 217; clinicl cut-off dte for OBOE: June 217); d Multiple occurrences of the sme dverse event (except for mlignncies) in one ptient re counted multiple times; e Rte per 1 PY (95% CI) s of 217; f Includes events occurring in 5% of ptients; g Includes events flling into the MedDRA versions 18., 18.1, 19.1 nd 2. SOC Infections nd Infesttions; h Non-serious MS relpses re not considered s n dverse event. If n dverse event reported term ws coded to the preferred term Multiple Sclerosis Relpse, regrdless of seriousness, it ws considered s n dverse event. When the MS relpse resulted in hospitliztion for ny reson other thn the routine tretment of the relpse, or when the hospitliztion ws prolonged, the relpse ws considered s serious dverse event; i Includes non-melnom skin cncer s per MedDRA version SMQ Mlignnt Tumours; j Reported s incidence rte per 1 PY of first mlignncy; k Serious infections re defined using dverse events flling into the MedDRA SOC Infections nd Infesttions, nd using Is the event non-serious or serious? from the dverse event cse report form. CI, confidence intervl; IFN, interferon; MedDRA, Medicl Dictionry for Regultory Activities; MS, multiple sclerosis; OCR, ocrelizumb; OIs, opportunistic infections; OLE, open-lbel extension; PY, ptient yers; SMQ, stndrdized MedDRA query; SOC, system orgn clss. 12
11 Rte Rte per 1 ptient yers of serious infections during the Phse III studies PPMS exposure (PY): 631 OCR; 235 PBO 547 OCR; 217 PBO 43 OCR; 186 PBO 42 OCR; 85 PBO 333 OCR 113 OCR RMS exposure (PY): 1,423 OCR; 793 IFN β-1 1,359 OCR; 66 IFN β-1 1,156 OCR 749 OCR 473 OCR 66 OCR Yer 1 Yer 2 Yer 3 Yer 4 Yer 5 Yer 6 RMS OCR RMS IFN β 1 PPMS OCR PPMS PBO Exposure to OCR nd comprtor (IFN β-1 or plcebo) in the Phse III pooled RMS nd PPMS popultions in totl PY. The exposure in Yer 5 nd Yer 6 (plcebo-treted ptients) ws too limited for ny meningful interprettion, thus these dt re not included in the plot. Investigtor text for dverse events ws encoded using MedDRA versions 18.1 nd Multiple occurrences of the sme dverse event in one ptient re counted multiple times. Serious infections re defined using dverse events flling into the MedDRA SOC Infections nd Infesttions, nd using Is the event non-serious or serious? from the dverse event cse report form. 95% CIs were clculted using n exct method bsed on the Poisson distribution. CI, confidence intervl; IFN, interferon; MedDRA, Medicl Dictionry for Regultory Activities; OCR, ocrelizumb; PBO, plcebo; PPMS, primry progressive multiple sclerosis; PY, ptient yers; RMS, relpsing multiple sclerosis; SOC, system orgn clss. 13
12 Crude incidence rte Crude incidence rte per 1 ptient yers of ll mlignncies over time compred with the Dnish MS registry 1. Ph II/Ph III nd OLEs popultion OCR ll-exposure popultion.8.43 (.26.66).44 (.29.65).4 (.26.59).45 (.31.64).45 (.32.63).48 (.35.64).6.2 (.5.5) Dnish Dnish.4.2 PBO+IFN β 1. Primry nlysis cut-off dte Jnury June Februry b The incidence rte of first mlignncy (number of first mlignncy events per 1 PY) ws clculted. Dnish MS registry:.67 (.63.71). Includes ptients who received ny dose of OCR during the controlled tretment nd ssocited OLE periods of the Phse II nd Phse III studies; b Includes ptients who received ny dose of OCR during the controlled tretment nd ssocited OLE periods of the Phse II nd Phse III studies, plus VELOCE, CHORDS, CASTING nd OBOE (s of 217; clinicl cut-off dte for OBOE: June 217). IFN, interferon; MS, multiple sclerosis; OCR, ocrelizumb; OLE, open-lbel extension; PBO, plcebo; PY, ptient yers. 15
13 Crude incidence rte Crude incidence rte per 1 ptient yers of ll mlignncies over time compred with the Dnish MS registry 1. Ph II/Ph III nd OLEs popultion OCR ll-exposure popultion.8.43 (.26.66).44 (.29.65).4 (.26.59).45 (.31.64).45 (.32.63).48 (.35.64).6.2 (.5.5) Dnish.4.2 PBO+IFN β 1. Primry nlysis cut-off dte Jnury June Februry b The incidence rte of first mlignncy (number of first mlignncy events per 1 PY) ws clculted. Dnish MS registry:.67 (.63.71). Includes ptients who received ny dose of OCR during the controlled tretment nd ssocited OLE periods of the Phse II nd Phse III studies; b Includes ptients who received ny dose of OCR during the controlled tretment nd ssocited OLE periods of the Phse II nd Phse III studies, plus VELOCE, CHORDS, CASTING nd OBOE (s of 217; clinicl cut-off dte for OBOE: June 217). IFN, interferon; MS, multiple sclerosis; OCR, ocrelizumb; OLE, open-lbel extension; PBO, plcebo; PY, ptient yers. 16
14 Age- nd sex-stndrdized incidence rte per 1 ptient yers of ll mlignncies over time compred with SEER dtbse Stndrdized incidence rte (.16.57) Primry nlysis cut-off dte b.26 (.15.49) Ph II/Ph III nd OLEs popultion.24 (.14.43).24 (.14.42).24 (.15.41) SEER.25 (.16.39) Jnury June Februry 216 b 216 b 216 b 217 b 217 c SEER The incidence rte of first mlignncy (number of first mlignncy events per 1 PY) ws clculted. SEER:.27 (.27.27). NMSC is not reported in SEER; b Includes ptients who received ny dose of OCR during the controlled tretment nd ssocited OLE periods of the Phse II nd Phse III studies; c Includes ptients who received ny dose of OCR during the controlled tretment nd ssocited OLE periods of the Phse II nd Phse III studies, plus VELOCE, CHORDS, CASTING nd OBOE (s of 217; clinicl cut-off dte for OBOE: June 217). NMSC, non-melnom skin cncer; OCR, ocrelizumb; OLE, open-lbel extension; PY, ptient yers; SEER, Surveillnce, Epidemiology, nd End Results. 17
15 Age- nd sex-stndrdized incidence rte per 1 ptient yers of ll mlignncies over time compred with SEER dtbse Stndrdized incidence rte (.16.57) Primry nlysis cut-off dte b.26 (.15.49) Ph II/Ph III nd OLEs popultion.24 (.14.43).24 (.14.42).24 (.15.41) OCR ll-exposure popultion.25 (.16.39) Jnury June Februry 216 b 216 b 216 b 217 b 217 c SEER The incidence rte of first mlignncy (number of first mlignncy events per 1 PY) ws clculted. SEER:.27 (.27.27). NMSC is not reported in SEER; b Includes ptients who received ny dose of OCR during the controlled tretment nd ssocited OLE periods of the Phse II nd Phse III studies; c Includes ptients who received ny dose of OCR during the controlled tretment nd ssocited OLE periods of the Phse II nd Phse III studies, plus VELOCE, CHORDS, CASTING nd OBOE (s of 217; clinicl cut-off dte for OBOE: June 217). NMSC, non-melnom skin cncer; OCR, ocrelizumb; OLE, open-lbel extension; PY, ptient yers; SEER, Surveillnce, Epidemiology, nd End Results. 18
16 Crude incidence rte Crude incidence rte per 1 ptient yers of femle brest cncer over time compred with three MS registries (Dnish, Swedish nd Cndin) 1. Ph II/Ph III nd OLEs popultion OCR ll-exposure popultion (.11.54) Swedish (.29).23 (.1.46).23 (.11.44).22 (.1.41).19 (.9.37) Dnish.21 (.11.37) Dnish. Primry nlysis cut-off dte PBO+IFN β 1 Cndin Cndin Jnury June Februry b The incidence rte of first mlignncy (number of first mlignncy events per 1 PY) ws clculted. Dnish MS registry:.21 (.18.23). Cndin British Columbi MS registry:.14 (.11.16). Swedish MS registry:.2 (.18.22). Includes ptients who received ny dose of OCR during the controlled tretment nd ssocited OLE periods of the Phse II nd Phse III studies; b Includes ptients who received ny dose of OCR during the controlled tretment nd ssocited OLE periods of the Phse II nd Phse III studies, plus VELOCE, CHORDS, CASTING nd OBOE (s of 217; clinicl cut-off dte for OBOE: June 217). IFN, interferon; MS, multiple sclerosis; OCR, ocrelizumb; OLE, open-lbel extension; PBO, plcebo; PY, ptient yers. 19
17 Crude incidence rte Crude incidence rte per 1 ptient yers of femle brest cncer over time compred with three MS registries (Dnish, Swedish nd Cndin) 1. Ph II/Ph III nd OLEs popultion OCR ll-exposure popultion (.11.54) Swedish (.29).23 (.1.46).23 (.11.44).22 (.1.41).19 (.9.37).21 (.11.37) Dnish. Primry nlysis cut-off dte PBO+IFN β 1 Cndin Jnury June Februry b The incidence rte of first mlignncy (number of first mlignncy events per 1 PY) ws clculted. Dnish MS registry:.21 (.18.23). Cndin British Columbi MS registry:.14 (.11.16). Swedish MS registry:.2 (.18.22). Includes ptients who received ny dose of OCR during the controlled tretment nd ssocited OLE periods of the Phse II nd Phse III studies; b Includes ptients who received ny dose of OCR during the controlled tretment nd ssocited OLE periods of the Phse II nd Phse III studies, plus VELOCE, CHORDS, CASTING nd OBOE (s of 217; clinicl cut-off dte for OBOE: June 217). IFN, interferon; MS, multiple sclerosis; OCR, ocrelizumb; OLE, open-lbel extension; PBO, plcebo; PY, ptient yers. 2
18 Stndrdized incidence rte Age-stndrdized incidence rte per 1 ptient yers of femle brest cncer over time compred with SEER dtbse 1. Ph II/Ph III nd OLEs popultion (.1.67).24 (.1.54).23 (.1.5).21 (.9.47).19 (.8.42).2 (.1.4).4.2 SEER SEER. Primry nlysis cut-off dte Jnury June Februry b The incidence rte of first mlignncy (number of first mlignncy events per 1 PY) ws clculted. SEER:.12 (.12.13). Includes ptients who received ny dose of OCR during the controlled tretment nd ssocited OLE periods of the Phse II nd Phse III studies; b Includes ptients who received ny dose of OCR during the controlled tretment nd ssocited OLE periods of the Phse II nd Phse III studies, plus VELOCE, CHORDS, CASTING nd OBOE (s of 217; clinicl cut-off dte for OBOE: June 217). OCR, ocrelizumb; OLE, open-lbel extension; PY, ptient yers; SEER, Surveillnce, Epidemiology, nd End Results. 21
19 Stndrdized incidence rte Age-stndrdized incidence rte per 1 ptient yers of femle brest cncer over time compred with SEER dtbse 1. Ph II/Ph III nd OLEs popultion OCR ll-exposure popultion (.1.67).24 (.1.54).23 (.1.5).21 (.9.47).19 (.8.42).2 (.1.4).4.2 SEER. Primry nlysis cut-off dte Jnury June Februry b The incidence rte of first mlignncy (number of first mlignncy events per 1 PY) ws clculted. SEER:.12 (.12.13). Includes ptients who received ny dose of OCR during the controlled tretment nd ssocited OLE periods of the Phse II nd Phse III studies; b Includes ptients who received ny dose of OCR during the controlled tretment nd ssocited OLE periods of the Phse II nd Phse III studies, plus VELOCE, CHORDS, CASTING nd OBOE (s of 217; clinicl cut-off dte for OBOE: June 217). OCR, ocrelizumb; OLE, open-lbel extension; PY, ptient yers; SEER, Surveillnce, Epidemiology, nd End Results. 22
20 Post-mrketing experience Mrket Dt cut-off: Mrch 218 Estimted number of ptients on OCR Exposure (PY) Rte of ftlities per 1 PY (95% CI) 37,171 14,67.28 (.21.4) Mortlity rtes from observtionl nd dtbse studies in the overll MS popultion between 1968 nd 215 rnged from.37 to.9 per 1 PY 1,2 Up to April 25, 218: No unconfounded cses of PML with ocrelizumb hve been reported Two confirmed cses of crry-over PML Both cses hve been reported by the treting physicins nd submitted to the regultors s relted to the previous tretment with either ntlizumb (cse 1) or fingolimod (cse 2) Exposure from compssionte-use progrm not ccounted for. CI, confidence intervl; MS, multiple sclerosis; OCR, ocrelizumb; PML, progressive multifocl leukoencephlopthy; PY, ptient yers. 1. Lery E, et l. PLoS One 215;1:e13233; 2. Goodin DS, et l. PLoS One 214;9:e1527; 3. Huser SL, et l. ECTRIMS 217; Poster
21 Conclusions The updted sfety profile in the ocrelizumb MS ll-exposure popultion is generlly consistent with tht seen during the controlled tretment period in the RMS nd PPMS popultions In the ocrelizumb ll-exposure popultion, the pooled RMS popultion nd the PPMS popultion, rtes per 1 PY of serious infections by yer fluctuted over time, without ny sustined increse One serious opportunistic infection (systemic Psteurell infection) hs been confirmed in ptients from ocrelizumb clinicl trils, s of 217 In the updted exposure period to 217, the rte of mlignncies in ocrelizumb-treted ptients remined within the rnge reported in epidemiologicl dt Long-term follow-up nd post-mrketing requirement studies will monitor ptient sfety, including identified nd potentil risks, in ptients with MS receiving ocrelizumb MS, multiple sclerosis; PPMS, primry progressive multiple sclerosis; PY, ptient yers; RMS, relpsing multiple sclerosis. 24
22 Acknowledgments We would like to thnk ll ptients, their fmilies, the investigtors, the independent dt monitoring committees, NeuroRx Reserch (Montrel, QC, Cnd), nd the Study Steering Committees who prticipted in these trils nd the ssocited open-lbel extensions: Phse II, OPERA I, OPERA II, ORATORIO, VELOCE, CHORDS, CASTING, OBOE This reserch ws sponsored by F. Hoffmnn-L Roche Ltd, Bsel, Switzerlnd. Writing nd editoril ssistnce for this presenttion ws provided by Articulte Science, UK, nd funded by F. Hoffmnn-L Roche Ltd, Bsel, Switzerlnd. 25
The RUTHERFORD-2 trial in heterozygous FH: Results and implications
The RUTHERFORD-2 tril in heterozygous FH: Results nd implictions Slide deck kindly supplied s n eductionl resource by Professor Derick Rl MD PhD Crbohydrte & Lipid Metbolism Reserch Unit University of
More informationPresented at the 75 th Annual Meeting of the American Academy of Dermatology, Orlando, FL, March 3-7, 2017 METHODS INTRODUCTION OBJECTIVE
Seven-Yer Interim Results from the ESPRIT 10-Yer Postmrketing Surveillnce Registry of Adlimumb for Moderte to Severe Psorisis Frncisco Kerdel, 1 Aln Menter, 2 Jshin J. Wu, 3 Mreike Bereswill, 4 Dilek Arikn,
More informationSafety and Tolerability of Subcutaneous Sarilumab and Intravenous Tocilizumab in Patients With RA
Sfety nd Tolerbility of Subcutneous Srilumb nd Intrvenous Tocilizumb in Ptients With RA Pul Emery, 1 Jun Rondon, 2 Anju Grg, 3 Hubert vn Hoogstrten, 3 Neil M.H. Grhm, 4 Ming Liu, 4 Nncy Liu, 3 Jnie Prrino,
More informationCheckMate 153: Randomized Results of Continuous vs 1-Year Fixed-Duration Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer
CheckMte 53: Rndomized Results of Continuous vs -Yer Fixed-Durtion Nivolumb in Ptients With Advnced Non-Smll Cell Lung Cncer Abstrct 297O Spigel DR, McCleod M, Hussein MA, Wterhouse DM, Einhorn L, Horn
More informationEfficacy of Pembrolizumab in Patients With Advanced Melanoma With Stable Brain Metastases at Baseline: A Pooled Retrospective Analysis
Efficcy of Pembrolizumb in Ptients With Advnced Melnom With Stble Brin Metstses t Bseline: A Pooled Retrospective Anlysis Abstrct 1248PD Hmid O, Ribs A, Dud A, Butler MO, Crlino MS, Hwu WJ, Long GV, Ancell
More informationEfficacy of Sonidegib in Patients With Metastatic BCC (mbcc)
AAD 216 eposter 3368 Efficcy of Sonidegib in Ptients With Metsttic BCC (mbcc) Colin Morton, 1 Michel Migden, 2 Tingting Yi, 3 Mnish Mone, 3 Dlil Sellmi, 3 Reinhrd Dummer 4 1 Stirling Community Hospitl,
More informationSeasonal influenza vaccination programme country profile: Ireland
Sesonl influenz vccintion progrmme country profile: Irelnd 2012 13 Seson Bckground informtion Influenz immunistion policy nd generl fcts bout Irelnd Volume indices of GDP per cpit in 2011 nd 2013 (EU-
More informationSYNOPSIS Final Abbreviated Clinical Study Report for Study CA ABBREVIATED REPORT
Finl Arevited Clinicl Study Report Nme of Sponsor/Compny: Bristol-Myers Squi Ipilimum Individul Study Tle Referring to the Dossier (For Ntionl Authority Use Only) Nme of Finished Product: Yervoy Nme of
More informationIMpower133: Primary PFS, OS, and safety in a Ph1/3 study of 1L atezolizumab + carboplatin + etoposide in extensive-stage SCLC
IMpower133: Primry PFS, OS, nd sfety in Ph1/3 study of 1L tezolizumb + crbopltin + etoposide in extensive-stge SCLC S. V. Liu, 1 A. S. Mnsfield, 2 A. Szczesn, 3 L. Hvel, 4 M. Krzkowski, 5 M. J. Hochmir,
More informationCommunity. Profile Powell County. Public Health and Safety Division
Community Helth Profile 2015 Powell County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More informationCommunity. Profile Big Horn County. Public Health and Safety Division
Community Helth Profile 2015 Big Horn County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationCommunity. Profile Yellowstone County. Public Health and Safety Division
Community Helth Profile 2015 Yellowstone County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationCommunity. Profile Lewis & Clark County. Public Health and Safety Division
Community Helth Profile 2015 Lewis & Clrk County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationCommunity. Profile Missoula County. Public Health and Safety Division
Community Helth Profile 2015 Missoul County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More informationCommunity. Profile Anaconda- Deer Lodge County. Public Health and Safety Division
Community Helth Profile 2015 Ancond- Deer Lodge County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12
More informationClinical Study Report Synopsis Drug Substance Naloxegol Study Code D3820C00018 Edition Number 1 Date 01 February 2013 EudraCT Number
EudrCT Number 2012-001531-31 A Phse I, Rndomised, Open-lbel, 3-wy Cross-over Study in Helthy Volunteers to Demonstrte the Bioequivlence of the Nloxegol 25 mg Commercil nd Phse III Formultions nd to Assess
More informationPNEUMOVAX 23 is recommended by the CDC for all your appropriate adult patients at increased risk for pneumococcal disease 1,2 :
PNEUMOVAX 23 is recommended y the CDC for ll your pproprite dult ptients t incresed risk for pneumococcl disese 1,2 : Adults ged
More informationSupplementary Online Content
Supplementry Online Content Zulmn DM, Pl Chee C, Ezeji-Okoye SC, et l. Effect of n intensive outptient progrm to ugment primry cre for high-need Veterns Affirs ptients: rndomized clinicl tril. JAMA Intern
More informationA review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital
MEDICAL ONCOLOGY A review of the ptterns of docetxel use for hormone-resistnt prostte cncer t the Princess Mrgret Hospitl S.N. Chin MD,* L. Wng MSc, M. Moore MD,* nd S.S. Sridhr MD MSc* ABSTRACT Bckground
More informationCommunity. Profile Carter County. Public Health and Safety Division
Community Helth Profile 2015 Crter County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More informationMortality of patients with multiple sclerosis: a cohort study in UK primary care
Mortlity of ptients with multiple sclerosis: cohort study in UK primry cre The Hrvrd community hs mde this rticle openly vilble. Plese shre how this ccess benefits you. Your story mtters Cittion Jick,
More informationClinicalTrials.gov Identifier: NCT
Efficcy of Drtumumb, Lenlidomide, nd Dexmethsone Versus Lenlidomide nd Dexmethsone in Relpsed or Refrctory Multiple Myelom Ptients With to 3 Prior Lines of Therpy: Updted Anlysis of POLLUX Sd Z. Usmni,
More informationkey words: bortezomib, multiple myeloma, retrospective analysis, treatment outcomes, subcutaneous, intravenous
reserch report Effect of Route of Bortezomib Administrtion on Tretment Outcomes in Previously Untreted Ptients with Multiple Myelom: A Retrospective Anlysis from US Community Oncology Prctices Robert M
More informationMetformin and breast cancer stage at diagnosis: a population-based study
ORIGINAL ARTICLE METFORMIN AND BREAST CANCER STAGE AT DIAGNOSIS, Leg et l. Metformin nd brest cncer stge t dignosis: popultion-bsed study I.C. Leg md msc,* K. Fung msc,* P.C. Austin phd, nd L.L. Lipscombe
More informationIncreased Relative Mortality in Women With Severe Oxygen-Dependent COPD
CHEST Originl Reserch Incresed Reltive Mortlity in Women With Severe Oxygen-Dependent COPD Mgnus Ekström, MD ; Krl A. Frnklin, MD, PhD ; nd Kerstin E. Ström, MD, PhD COPD Bckground: Although the incidence
More informationAddendum to the Evidence Review Group Report on Aripiprazole for the treatment of schizophrenia in adolescents (aged years)
Addendum to the Evidence Review Group Report on Aripiprzole for the tretment of schizophreni in dolescents (ged 15-17 yers) Produced by Authors Correspondence to Southmpton Helth Technology Assessments
More informationStart ORKAMBI today. INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION. Sydney Age 4
F O R H E A L T H C A R E P R O F E S S I O N A L S For ptients ge 2 yers nd older who re homozygous for the F508del muttion 1,2 Modify the course. Strt tody. Sydney Age 4 F508del/F508del INDICATIONS AND
More informationEmerging Options for Thromboprophylaxis After Orthopedic Surgery: A Review of Clinical Data
Emerging Options for Thromboprophylxis After Orthopedic Surgery: A Review of Clinicl Dt Bob L. Lobo, Phrm.D. In four rndomized, controlled studies of ptients undergoing orthopedic surgery, the ntithrombotic
More informationAbstract. Background. Aim. Patients and Methods. Patients. Study Design
Impct of the Use of Drugs nd Substitution Tretments on the Antivirl Tretment of Chronic Heptitis C: Anlysis of Complince, Virologicl Response nd Qulity of Life (CHEOBS). Melin, 1 J.-. Lng, D. Ouzn, 3 M.
More informationIntroduction. These patients benefit less from conventional chemotherapy than patients identified as MMR proficient or microsatellite stable 3-5
Nivolumb + Ipilimumb Combintion in Ptients With DNA Mismtch Repir-Deficient/Microstellite Instbility-High Metsttic Colorectl Cncer: First Report of the Full Cohort From CheckMte-142 Abstrct 553 André T,
More informationMEDALIST Trial Background and Rationale
The MEDALIST Tril: Results of Phse 3, Rndomized, Double-Blind, Plcebo-Controlled Study of to Tret Ptients With Very Low-, Low-, or Intermedite-Risk Myelodysplstic Syndromes (MDS) Associted Anemi With Ring
More informationUS Food and Drug Administration-Mandated Trials of Long-Acting b -Agonists Safety in Asthma. Samy Suissa, PhD ; and Amnon Ariel, MD, FCCP
CHEST Commentry US Food nd Drug Administrtion-Mndted Trils of Long-Acting b -Agonists Sfety in Asthm Will We Know the Answer? Smy Suiss, PhD ; nd Amnon Ariel, MD, FCCP For 2 decdes, long-cting b -gonists
More informationSponsor / Company: Sanofi Drug substance(s): AVE0005 (aflibercept)
These results re supplied for informtionl purposes only. Prescribing decisions should be mde bsed on the pproved pckge insert in the country of prescription. Sponsor / Compny: Snofi Drug substnce(s): AVE0005
More informationImmune-Mediated Adverse Reactions Management Guide
Immune-Medited Adverse Rections Mngement Guide INDICATIONS AND USAGE YERVOY (ipilimumb) is indicted for: Tretment of unresectble or metsttic melnom in dults nd peditric ptients (12 yers nd older) Adjuvnt
More informationEconomic evaluation of sublingual vs subcutaneous allergen immunotherapy Jitka Pokladnikova, MSc, Pharm*; Irena Krcmova, MD ; and Jiri Vlcek, PhD*
Economic evlution of sublingul vs subcutneous llergen immunotherpy Jitk Pokldnikov, MSc, Phrm*; Iren Krcmov, MD ; nd Jiri Vlcek, PhD* Bckground: Sublingul llergen immunotherpy (SLIT) is commonly used lterntive
More informationUniversity of Texas Health Science Center, San Antonio, San Antonio, Texas, USA
Lung Cncer Chemotherpy Given Ner the End of Life by Community Oncologists for Advnced Non-Smll Cell Lung Cncer Jose R. Murillo, Jr., Jim Koeller b,c Methodist Hospitl, Houston, Texs, USA; b University
More informationOriginal Article. T Akter 1, N Islam 2, MA Hoque 3, S Khanam 4, HA khan 5, BK Saha 6. Abstract:
Fridpur Med. Coll. J. 214;9(2):61-67 Originl Article Nebuliztion by Isotonic Mgnesium Sulphte Solution with Provide Erly nd Better Response s Compred to Conventionl Approch ( Plus Norml Sline) in Acute
More informationMultiple sclerosis (MS) affects approximately. Triaging Patients with Multiple Sclerosis in the Emergency Department. Room for Improvement
Systemtic Review of Tools for Anxiety in MS MS CARE DELIVERY: CHALLENGES AND INVATIONS Triging Ptients with Multiple Sclerosis in the Emergency Deprtment Room for Improvement Heshm Abboud, MD, PhD; Krin
More informationAnalysis of Risk Factors for the Development of Incisional and Parastomal Hernias in Patients after Colorectal Surgery
Originl Article Journl of the Koren Society of J Koren Soc Coloproctol 2012;28(6):299-303 http://dx.doi.org/10.3393/jksc.2012.28.6.299 pissn 2093-7822 eissn 2093-7830 Anlysis of Risk Fctors for the Development
More informationSee 17 for PATIENT COUNSELING INFORMATION and Medication Guide. Revised: 10/2017
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use sfely nd effectively. See full prescribing informtion for. (ipilimumb) injection, for intrvenous use
More informationOlanzapine for the prophylaxis and rescue of chemotherapyinduced nausea and vomiting (CINV): a retrospective study
Originl Article Olnzpine for the prophylxis nd rescue of chemotherpyinduced nuse nd vomiting (CINV): retrospective study Leonrd Chiu, Nichols Chiu, Ronld Chow, Liying Zhng, Mrk Psetk, Jordn Stinson, Brenne
More informationY. Yazici 1, D. Moniz Reed 2, C. Klem 2, L. Rosenblatt 2, G. Wu 2, J.M. Kremer 3
Greter remission rtes in ptients with erly versus long-stnding disese in biologic-nive rheumtoid rthritis ptients treted with btcept: post hoc nlysis of rndomised clinicl tril dt Y. Yzici 1, D. Moniz Reed
More informationInhaled Corticosteroids and the Risk of Pneumonia in People With Asthma
CHEST Originl Reserch Inhled Corticosteroids nd the Risk of Pneumoni in People With Asthm A Cse-Control Study Trici McKeever, PhD ; Timothy W. Hrrison, MD ; Richrd Hubbrd, MD ; nd Dominick Shw, MD ASTHMA
More informationAntiviral Therapy 2015; 20: (doi: /IMP2874)
Antivirl Therpy 25; 2:79 79 (doi:.385/imp2874) Originl rticle Single dose permivir for the tretment of cute sesonl influenz: integrted nlysis of efficcy nd sfety from two plcebo-controlled trils Richrd
More informationEstimating the impact of the 2009 influenza A(H1N1) pandemic on mortality in the elderly in Navarre, Spain
Rpid communictions Estimting the impct of the influenz pndemic on mortlity in the elderly in Nvrre, Spin J Cstill (jcstilc@nvrr.es) 1, J Etxeberri 1, E Ardnz 1, Y Floristán 1, R López Escudero 1, M Guevr
More informationInvasive Pneumococcal Disease Quarterly Report. July September 2017
Invsive Pneumococcl Disese Qurterly Report July September 2017 Prepred s prt of Ministry of Helth contrct for scientific services by Rebekh Roos Helen Heffernn October 2017 Acknowledgements This report
More informationBright Futures Medical Screening Reference Table 2 to 5 Day (First Week) Visit
Bright Futures Medicl Reference Tle 2 to 5 Dy (First Week) Visit Universl Action Metolic nd Verify documenttion of neworn metolic screening results, pproprite rescreening, nd needed follow-up. Document
More informationTR Spitzer 1, CJ Friedman 2, W Bushnell 2, SR Frankel 3, J Raschko 4. Summary:
(2000) 26, 203 210 2000 Mcmilln Publishers Ltd All rights reserved 0268 3369/00 $15.00 www.nture.com/bmt Double-blind, rndomized, prllel-group study on the efficcy nd sfety of orl grnisetron nd orl ondnsetron
More informationMetabolic Syndrome and Health-related Quality of Life in Obese Individuals Seeking Weight Reduction
Metbolic Syndrome nd Helth-relted Qulity of Life in Obese Individuls Seeking Weight Reduction Adm Gilden Tsi 1, Thoms A. Wdden 1, Dvid B. Srwer 1, Robert I. Berkowitz 1, Leslie G. Womble 1, Louise A. Hesson
More informationEuropean Journal of Internal Medicine
Europen Journl of Internl Medicine 22 (2011) 399 406 Contents lists vilble t ScienceDirect Europen Journl of Internl Medicine journl homepge: www.elsevier.com/locte/ejim Originl rticle Incidence of cute
More informationThe incidence of melanoma, the most serious
Efectiveness nd sfety of ipilimumb therpy in dvnced melnom: evidence from clinicl prctice sites in the US Kim A Mrgolin, MD, Ahmd Trhini, MD, PhD, b Sumti Ro, PhD, c Monic Ktyl, JD, MPH, d I-Fen Chng,
More informationClinical Evidence for Second- and Third-Line Treatment Options in Advanced Non-Small Cell Lung Cancer
Clinicl Evidence for Second- nd Third-Line Tretment Options in Advnced Non-Smll Cell Lung Cncer Filippo de Mrinis, Frncesco Grossi b Thorcic Oncology Unit I, Deprtment of Lung Diseses, Sn Cmillo nd Forlnini
More informationInput from external experts and manufacturer on the 2 nd draft project plan Stool DNA testing for early detection of colorectal cancer
Input externl experts nd mnufcturer on the 2 nd drft project pln Stool DNA testing for erly detection of colorectl cncer (Project ID:OTJA10) All s nd uthor s replies on the 2nd drft project pln Stool DNA
More informationULTOMIRIS is administered once every 8 weeks a
(rvulizumb-cwvz) for the tretment of dult ptients with proxysml nocturnl hemoglobinuri (PNH) is dministered once every 8 weeks PATIENTS STARTING WITH NO PRIOR TREATMENT FOR PNH THE RECOMMENDED DOSING REGIMEN
More informationRisk of Colorectal Cancer by Subsite in a Swedish Prostate Cancer Cohort
Specil Report Risk of Colorectl Cncer by Subsite in Swedish Prostte Cncer Cohort Yunxi Lu, MD, PhD, Rickrd Ljung, MD, PhD, Ann Mrtling, MD, PhD, nd Mts Lindbld, MD, PhD Bckground: The reltionship between
More informationLevofloxacin in the Treatment of Pneumonia Caused by Streptococcus pneumoniae, Including Multidrug-Resistant Strains
Levofloxcin in the Tretment of Pneumoni Cused by Streptococcus pneumonie, Including Multidrug-Resistnt Strins Review Jnet Peterson, PhD Ortho-McNeil Jnssen Scientific Affirs, LLC; Rritn, New Jersey, USA
More informationTrends in antihypertensive and lipidlowering therapy in subjects with type II diabetes: clinical effectiveness or clinical discretion?
ORIGINAL ARTICLE Trends in ntihypertensive nd lipidlowering therpy in subjects with type II dibetes: clinicl effectiveness or clinicl discretion? MC Gulliford, J Chrlton nd R Ltinovic Deprtment of Public
More informationAntiviral Therapy 2015; 20: (doi: /IMP2825)
Antivirl Therpy 2015; 20:209 216 (doi: 10.3851/IMP2825) Originl rticle Cost-effectiveness of boceprevir co-dministrtion versus pegylted interferon-2b nd ribvirin only for ptients with heptitis C genotype
More informationPrognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with nonmetastatic
Crcinogenesis, 2015, Vol. 36, No. 2, 243 248 doi:10.1093/crcin/bgu247 Advnce Access publiction December 18, 2014 Originl Mnuscript originl mnuscript Prognostic significnce of pretretment serum levels of
More informationManagement of Relapsed/Refractory Follicular Lymphoma
April 2018 Volume 16, Issue 4, Supplement 10 Mngement of Relpsed/Refrctory Folliculr Lymphom n How I Tret Relpsed/Refrctory Folliculr Lymphom: An Expert Perspective n Highlights from: The 2017 Americn
More informationPotential for Interactions Between Dietary Supplements and Prescription Medications a
CLINICAL RESEARCH STUDY Potentil for Interctions Between Dietry Supplements nd Prescription Medictions Amit Sood, MD, MSc, Rich Sood, MD, b Frncis J. Brinker, ND, Rvneet Mnn, MBBS, c Lur L. Loehrer, Dietlind
More informationmsmr MEDICAL SURVEILLANCE MONTHLY REPORT INSIDE THIS ISSUE: A publication of the Armed Forces Health Surveillance Center Summary tables and figures
VOL. 17 NO. 09 SEPTEMBER 2010 msmr A publiction of the Armed Forces Helth Surveillnce Center MEDICAL SURVEILLANCE MONTHLY REPORT Source: CDC INSIDE THIS ISSUE: Contct trnsfer of vccini virus from U.S.
More informationBreast-Conserving Surgery Under Local Anesthesia in Elderly Patients with Severe Cardiorespiratory Comorbidities: A Hospital-Based Case-Control Study
Originl Article Brest Cre 2017;12:29 33 DOI: 10.1159/000455003 Published online: Februry 8, 2017 Brest-Conserving Surgery Under Locl in Elderly Ptients with Severe Crdiorespirtory Comorbidities: A Hospitl-Bsed
More informationSee 17 for PATIENT COUNSELING INFORMATION and FDAapproved patient labeling. Revised: 6/2016 FULL PRESCRIBING INFORMATION: CONTENTS*
1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use BASAGLAR sfely nd effectively. See full prescribing informtion for BASAGLAR BASAGLAR (insulin glrgine
More informationAnalysis of alternatives for insulinizing patients to achieve glycemic control and avoid accompanying risks of hypoglycemia
284 Anlysis of lterntives for izing ptients to chieve glycemic control nd void ccompnying risks of hypoglycemi JIALIN GAO 1,2*, QIANYIN XIONG 1,2*, JUN MIAO 1*, YAO ZHANG 2,3, LIBING XIA 1, MEIQIN LU 1,
More informationComparison of claims data on hospitalization rates and repeat procedures in patients receiving a bowel preparation prior to colonoscopy
727999SMO0010.1177/2050312117727999SAGE Open MedicineYoung et l. reserch-rticle2017 Originl Article SAGE Open Medicine Comprison of clims dt on hospitliztion rtes nd repet procedures in ptients receiving
More informationManagement and Outcomes of Binge-Eating Disorder in Adults: Current State of the Evidence
Clinicin Summry Mentl Helth Eting Disorders Mngement nd Outcomes of Binge-Eting Disorder in Adults: Current Stte of the Evidence Focus of This Summry This is summry of systemtic review evluting the evidence
More informationThe potential future of targeted radionuclide therapy: implications for occupational exposure? P. Covens
The potentil future of trgeted rdionuclide therpy: implictions for occuptionl exposure? Introduction: Trgeted Rdionuclide Therpy (TRT) Systemic tretment Molecule lbelled with rdionuclide delivers toxic
More informationTarget: 10 mg/day within several days Schizophrenia in adolescents (2.1)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ZYPREXA sfely nd effectively. See full prescribing informtion for ZYPREXA. ZYPREXA (olnzpine) Tblet
More informationInvasive Pneumococcal Disease Quarterly Report July September 2018
Invsive Pneumococcl Disese Qurterly Report July Septemer Introduction Since 17 Octoer 2008, invsive pneumococcl disese (IPD) hs een notifile to the locl Medicl Officer of Helth under the Helth Act 1956.
More informationChilblains (pernio, perniosis) are cold-induced, painful or itching
Nifedipine vs Plcebo for Tretment of Chronic Chilblins: A Rndomized Controlled Tril Ibo H. Souwer, MD 1 Jcobus H. J. Bor, BSc (Mth) 2 Pul Smits, MD, PhD 3 Antoine L. M. Lgro-Jnssen, MD, PhD 1 1 Deprtment
More informationResults. Table 1: Demographic and Baseline Characteristics, Open-Label Safety Population Prior Double-Blind OC/APAP ER (n=77)
Open-Lbel Extension of Rndomized, Double-Blind, Plcebo-Controlled, Phse 3 Study of the Sfety nd Anlgesic Efficcy of MNK-795 Oxycodone/Acetminophen Extended-Relese (OC/APAP ER) Tblets in n Acute Pin Model
More informationImpact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors
Originl Article Impct of Positive Nodl Metstses in Ptients with Thymic Crcinom nd Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, nd Jennifer L. Sullivn, MD Introduction: Thymic crcinoms
More informationWeight-Based Dosage Regimen: (2.1) Body Weight Range (kg) Loading Dose (mg) Maintenance Dose (mg) greater or equal to 40 to less than 60 2,400 3,000
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use sfely nd effectively. See full prescribing informtion for. (rvulizumb-cwvz) injection, for intrvenous
More informationEstimated Prevalence and Economic Burden of Severe, Uncontrolled Asthma in the United States
Estimted Prevlence nd Economic Burden of Severe, Uncontrolled Asthm in the United Sttes Cheryl S. Hnkin 1 ; Amy Bronstone 1 ; Zhohui Wng 1 ; Mry Butti-Smll 2 ; Philip O. Buck 2 1 BioMedEcon, Moss Bech,
More informationEsophageal carcinoma is the eighth most common cancer
ORIGINAL ARTICLE Tumor-Strom Rtio Is n Independent Predictor for Survivl in Esophgel Squmous Cell Crcinom Ki Wng, MD,* Wei M, MD,* Jinbo Wng, MD,* Ling Yu, MD, Xiomei Zhng, MD, Zhenbo Wng, MD, Bingxu Tn,
More informationINVEGA SUSTENNA (paliperidone palmitate) extended-release injectable
(pliperidone plmitte) extended-relese injectble suspension, for intrmusculr use HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use sfely nd effectively.
More informationUrinary Tract Infection in Men
C H A P T E R 1 9 Urinry Trct Infection in Men Toms L. Griebling, MD Associte Professor & Vice Chir of Urology University of Knss Knss City, Knss Contents INTRODUCTION........................................623
More informationThese highlights do not include all the information needed to use ADVATE safely and effectively. See full prescribing information for ADVATE.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ADVATE sfely nd effectively. See full prescribing informtion for ADVATE. ADVATE [Antihemophilic Fctor
More informationImpact of Pharmacist Intervention on Diabetes Patients in an Ambulatory Setting
Impct of Phrmcist Intervention on Dibetes Ptients in n Ambultory Setting Julie Stding, PhrmD, CDE, Jmie Herrmnn, PhrmD, Ryn Wlters, MS, Chris Destche, PhrmD, nd Aln Chock, PhrmD Dibetes is the seventh-leding
More informationkey words: chronic obstructive pulmonary disease, beta agonists, Medicare, health care costs, health care utilization
reserch report Helth Cre Use nd Costs Among Medicre Ptients With Chronic Obstructive Pulmonry Disese Treted With Short-Acting Bet Agonists or Long-Acting Bet Agonists Flvi Ejzykowicz, PhD; 1 Vmsi K Bollu,
More informationINVEGA SUSTENNA (paliperidone palmitate) extended-release injectable
(pliperidone plmitte) extended-relese injectble suspension, for intrmusculr use HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use sfely nd effectively.
More informationOriginal Article. Breast Care 2016;11: DOI: /
Originl Article Brest Cre 2016;11:323 327 DOI: 10.1159/000452079 Published online: October 24, 2016 Neodjuvnt Chemotherpy with Docetxel, Crbopltin nd Weekly Trstuzumb Is Active in HER2-Positive Erly Brest
More informationReport of the Conference on Low Blood
1046 Report of the Conference on Low Blood Cholesterol: Mortlity Associtions Dvid Jcobs, PhD; Henry Blckburn, MD; Millicent Higgins, MD; Dwyne Reed, MD, PhD; Hiroysu Iso, MD; Grdner McMilln, MD, PhD; Jmes
More informationRisks for All-Cause Mortality: Stratified by Age, Estimated Glomerular Filtration Rate and Albuminuria
Clinicl Prctice: Mini-Review Received: My 20, 2016 Accepted fter revision: December 14, 2016 Published online: Jnury 27, 2017 Risks for All-Cuse Mortlity: Strtified by Age, Estimted Glomerulr Filtrtion
More informationXII. HIV/AIDS. Knowledge about HIV Transmission and Misconceptions about HIV
XII. HIV/AIDS Knowledge bout HIV Trnsmission nd Misconceptions bout HIV One of the most importnt prerequisites for reducing the rte of HIV infection is ccurte knowledge of how HIV is trnsmitted nd strtegies
More informationUNLOCKING SELF-POTENTIAL
ADVATE is FDA pproved for prophylxis in both dults & children (0-16 yers) 1 UNLOCKING SELF-POTENTIAL Setting Gols Worksheet Plese see pge 3 for ADVATE Indictions nd Detiled Importnt Risk Informtion. Plese
More informationFischer H, Kheifets L, Huss A, Peters T.L., Vermeulen R, Ye W, Fang F, Wiebert P, Vergara X.P., Feychting M
Supplementry mteril: A Nested Cse-Control Study of Occuptionl Exposure to Electric Shocks nd Mgnetic Fields nd Amyotrophic Lterl Sclerosis in Sweden from 1991 to 2010 Fischer H, Kheifets L, Huss A, Peters
More informationPatient 1: 31-Year-Old Female. Fingolimod treatment
Cell Counts (10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Lymphocyte Pharmacodynamics and Safety of Use in Patients Previously
More informationRelation of Tumor Size, Lymph Node Status, and Survival in
Reltion of Tumor Size, Lymph Node Sttus, nd Survivl in 24,74 Brest Cncer Cses CHRISTINE L. CARTER, PHD, MPH,* CAROL ALLEN, PHD,t AND DONALD E. HENSON, MD* Two of the most importnt prognostic indictors
More informationWork-related musculoskeletal disorders (WMSDs) among nursing personnel
Work-Relted Musculoskeletl Injuries nd Disorders Among Occuptionl nd Physicl Therpists Amy R. Drrgh, Wendy Huddleston, Phyllis King KEY WORDS ccidents, occuptionl moving nd lifting ptients musculoskeletl
More informationA community-based comparison of trauma patient outcomes between D- and L-lactate fluids,
Americn Journl of Emergency Medicine (2013) 31, 206 214 www.elsevier.com/locte/jem Originl Contribution A community-bsed comprison of trum ptient outcomes between D- nd L-lctte fluids, Kzuki Kuwbr PhD,,
More informationRelationship Between Hospital Performance on a Patient Satisfaction Survey and Surgical Quality
Reserch Originl Investigtion Reltionship Between Hospitl Performnce on Ptient Stisfction Survey nd Surgicl Qulity Greg D. Scks, MD, MPH; Elise H. Lwson, MD, MSHS; Aron J. Dwes, MD; Mrci M. Russell, MD;
More informationEffectiveness of Belt Positioning Booster Seats: An Updated Assessment
ARTICLES Effectiveness of Belt Positioning Booster Sets: An Updted Assessment AUTHORS: Kristy B. Arbogst, PhD, Jessic S. Jermkin, DSc, Michel J. Klln, MS, b nd Dennis R. Durbin, MD, MSCE,b Center for Injury
More informationBilling and Coding Guide. Hospital Outpatient Department
illing nd oding Guide Hospitl Outptient Deprtment overge, coding, nd pyment in the hospitl outptient deprtment ONPTTRO (ptisirn) received US Food nd Drug dministrtion (FD) pprovl on 10 ug 2018, nd is indicted
More information7Disconnect the syringe from the. 9Reconnect the syringe to the ADVATE
TROUBLESHOOTING GUIDE The following instructions will guide you through recovering ADVATE if the initil reconstitution procedure does not work. Some steps my need to be repeted from this initil reconstitution
More informationSupplementary Online Content
Supplementry Online Content Rieckmnn N, Kronish IM, Shpiro PA, Whng W, Dvidson KW. Serotonin reuptke inhibitor use, depression, nd long-term outcomes fter n cute coronry : prospective cohort study. JAMA
More informationExcessive sleepiness is a cardinal symptom of many sleep disorders,
SCIENTIFIC INVESTIGATIONS Evlution of the Sfety of Modfinil for Tretment of Excessive Sleepiness Thoms Roth, Ph.D. 1 ; Jonthn R.L. Schwrtz, M.D. 2 ; Mx Hirshkowitz, Ph.D. 3 ; Milton K. Ermn, M.D. 4 ; Jeffrey
More information